The intensity of radiotherapy-elicited immune response is associated with esophageal cancer clearance

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Ma, Jin Lu ^a   Jin, Long ^a   Li, Yao Dong ^b   He, Chen Chen ^a   Guo, Xi Jing ^a   Liu, Rui ^a   Yang, Yun Yi ^a   Han, Su Xia ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b XI'AN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; ENDOSCOPY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGOGRAPHY; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; PROTEIN BLOOD LEVEL; RADIATION INJURY; SKIN TOXICITY; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; VOMITING; BLOOD; CANCER STAGING; ESOPHAGEAL NEOPLASMS; GAMMA RADIATION; IMMUNOLOGY; MIDDLE AGED; PATHOLOGY; RADIATION RESPONSE; THERAPEUTIC USE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DOSE-RESPONSE RELATIONSHIP, RADIATION; ESOPHAGEAL NEOPLASMS; FEMALE; GAMMA RAYS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-2; MALE; MIDDLE AGED; NEOPLASM STAGING; TUMOR MICROENVIRONMENT;

EID: 84902139018     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/794249     Document Type: Article

References (25)

1. Semrau R., Herzog S. L., Vallbohmer D., Kocher M., Holscher A., Muller R. P., Radiotherapy in elderly patients with inoperable esophageal cancer. Is there a benefit? Strahlentherapie und Onkologie 2012 188 226 232
2. Vallböhmer D., Hölscher A. H., Brabender J., Prenzel K., Gutschow C., Schröder W., Metzger R., Bollschweiler E., Clinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma: Is there really a difference? Diseases of the Esophagus 2008 21 7 596 600 2-s2.0-53149147454 10.1111/j.1442-2050.2008.00817.x
3. Farzad M., de Luca M. C., Rubino G., Pirtoli L., Pepi F., Sebaste L., Ponticelli P., Atzeni G., Maranzano E., Silvano G., Chemotherapy and concurrent irradiation, intended to cure, for stage III-IV oesophageal cancer. Radiologia Medica 2001 102 1-2 72 77 2-s2.0-0035409785 (Pubitemid 33613804)
4. Perez C. A., Mutic S., Advances and future of Radiation Oncology. Reports of Practical Oncology and Radiotherapy 2013 18 329 332
5. Khan K. H., Blanco-Codesido M., Molife L. R., Cancer therapeutics: targeting the apoptotic pathway. Critical Reviews in Oncology/Hematology 2013 13 S1040 S8428
6. Lavelle C., Foray N., Chromatin structure and radiation-induced DNA damage: from structural biology to radiobiology. The International Journal of Biochemistry & Cell Biology 2014 49 84 97
7. Ganss R., Ryschich E., Klar E., Arnold B., Hämmerling G. J., Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Research 2002 62 5 1462 1470 2-s2.0-0036494443 (Pubitemid 34407808)
8. Wu C. Y., Yang L. H., Yang H. Y., Knoff J., Peng S., Lin Y. H., Wang C., Alvarez R. D., Pai S. I., Roden R. B., Hung C. F., Wu T. C., Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clinical Cancer Research 2014 20 644 657
9. de la Cruz-Merino L., Barco-Sanchez A., Henao Carrasco F., Nogales Fernandez E., Vallejo Benitez A., Brugal Molina J., Martinez Peinado A., Grueso Lopez A., Ruiz Borrego M., Codes Manuel de Villena M., Sanchez-Margalet V., Nieto-Garcia A., Alba Conejo E., Casares Lagar N., Ibanez Martinez J., New insights into the role of the immune microenvironment in breast carcinoma. Clinical and Developmental Immunology 2013 2013 11 10.1155/2013/785317 785317
10. Candido E. B., Silva L. M., Carvalho A. T., Lamaita R. M., Filho R. M., Cota B. D., da Silva-Filho A. L., Immune response evaluation through determination of type 1, type 2, and type 17 patterns in patients with epithelial ovarian cancer. Reproductive Sciences 2013 20 828 837
11. Lee J., Lim K. T., SJSZ glycoprotein (38kDa) prevents thymus atrophy and enhances expression of IL-2 and IL-12 in diethylnitrosamine-induced hepatocarcinogenesis. International Immunopharmacology 2012 13 362 369
12. Buchser W. J., Laskow T. C., Pavlik P. J., Lin H. M., Lotze M. T., Cell-mediated autophagy promotes cancer cell survival. Cancer Research 2012 72 2970 2979
13. Ingersoll S. B., Stoltzfus G. P., Merchant M. H., Ahmad S., Edwards C. R., Ahmed A., Oyer J. L., Finkler N. J., Holloway R. W., Edwards J. R., Comparison of the cytotoxic response against ovarian cancer by immune effector cells isolated and expanded from normal donors and ovarian cancer patients. Cytotherapy 2012 14 716 723
14. Utsumi T., Suyama T., Imamura Y., Fuse M., Sakamoto S., Nihei N., Ueda T., Suzuki H., Seki N., Ichikawa T., The Association of CXCR3 and Renal Cell Carcinoma Metastasis. The Journal of Urology 2014 10.1016/j.juro.2014.01.100
15. Gogoi D., Chiplunkar S. V., Targeting gamma delta T cells for cancer immunotherapy: bench to bedside. Indian Journal of Medical Research 2013 138 755 761
16. Fielding C. A., Jones G. W., McLoughlin R. M., McLeod L., Hammond V. J., Uceda J., Williams A. S., Lambie M., Foster T. L., Liao C. T., Rice C. M., Greenhill C. J., Colmont C. S., Hams E., Coles B., Kift-Morgan A., Newton Z., Craig K. J., Williams J. D., Williams G. T., Davies S. J., Humphreys I. R., 'Donnell V. B. O., Taylor P. R., Jenkins B. J., Topley N., Jones S. A., Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity 2014 40 40 50
17. Christensen E., Pintilie M., Evans K. R., Lenarduzzi M., Ménard C., Catton C. N., Diamandis E. P., Bristow R. G., Longitudinal cytokine expression during IMRT for prostate cancer and acute treatment toxicity. Clinical Cancer Research 2009 15 17 5576 5583 2-s2.0-69949099189 10.1158/1078-0432.CCR-09-0245
18. Nakashima T., Uematsu N., Shibamori M., Sakurai K., Ishida T., Establishment of an X-ray irradiation-induced glossitis model in rats: biphasic elevation of proinflammatory cytokines and chemokines. Journal of Pharmacology and Experimental Therapeutics 2013 347 660 668
19. Kato H., Sato A., Fukuda H., Kagami Y., Udagawa H., Togo A., Ando N., Tanaka O., Shinoda M., Yamana H., Ishikura S., A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Japanese Journal of Clinical Oncology 2009 39 10 638 643 2-s2.0-70349975980 10.1093/jjco/hyp069
20. Yanagawa M., Tatsumi M., Miyata H., Morii E., Tomiyama N., Watabe T., Isohashi K., Kato H., Shimosegawa E., Yamasaki M., Mori M., Doki Y., Hatazawa J., Evaluation of response to neoadjuvant chemotherapy for esophageal cancer: PET response criteria in solid tumors versus response evaluation criteria in solid tumors. Journal of Nuclear Medicine 2012 53 872 880
21. Tosti G., Cocorocchio E., Pennacchioli E., Anti-cytotoxic T lymphocyte antigen-4 antibodies in melanoma. Clinical, Cosmetic and Investigational Dermatology 2013 6 245 256
22. Teitz-Tennenbaum S., Li Q., Okuyama R., Davis M. A., Sun R., Whitfield J., Knibbs R. N., Stoolman L. M., Chang A. E., Mechanisms involved in radiation enhancement of intratumoral dendritic cell therapy. Journal of Immunotherapy 2008 31 4 345 358 2-s2.0-42649099297 10.1097/CJI.0b013e318163628c (Pubitemid 351595157)
23. Lumniczky K., Safrany G., The impact of radiation therapy on the antitumor immunity: local effects and systemic consequences. Cancer Letters 2013 10.1016/j.canlet.2013.08.024
24. Shiiba K., Suzuki R., Kawakami K., Interleukin 2-activated killer cells: Generation in collaboration with interferon γ and its suppression in cancer patients. Cancer Immunology, Immunotherapy 1986 21 2 119 128 2-s2.0-0022653306 (Pubitemid 16155058)
25. Maxwell W., McDevitt J., Reid I., Sharpe I., Feighery C., Tanner W. A., Emmons R., Monson J. R. T., Changes in immunological parameters during interleukin 2 and interferon 2 alpha treatment of recurrent renal cell carcinoma and malignant melanoma. European Journal of Surgical Oncology 1993 19 3 265 272 2-s2.0-0027302957 (Pubitemid 23215441)